Search results
Results From The WOW.Com Content Network
2014 – Merck KGaA announced that it would purchase Sigma-Aldrich for approx. $17 billion (€13.1 billion). [16] [17] November 3, 2014 – Sigma-Aldrich filed a definitive proxy statement with the U.S. Securities and Exchange Commission to hold a special investors meeting regarding approval for the sale to Merck KGaA. [18]
The first edition of the Merck's Index was published in 1889 by the German chemical company Emanuel Merck and was primarily used as a sales catalog for Merck's growing list of chemicals it sold. [2] The American subsidiary was established two years later and continued to publish it.
The Merck Manuals (outside the U.S. and Canada: The MSD Manuals; Chinese: 默沙东诊疗手册; pinyin: Mòshādōng Zhěnliáo Shǒucè) are medical references published by the American pharmaceutical company Merck & Co. (known as MSD outside the United States and Canada), that cover a wide range of medical topics, including disorders, tests, diagnoses, and drugs.
Jul. 23—RIVERSIDE — Merck plans to cease production at the Cherokee manufacturing site in Riverside by the end of the year. In 2022, Merck announced its intentions to phase out the Cherokee ...
"NIOSH". 2 August 2024. 677 NIST Webbook NIST Chemistry Webbook National Institute of Standards and Technology: spectra CAS ionization energy mass spectrum, InChI C+CAS "NIST Webbook". NMRShiftDB University of Cologne: organic nuclear magnetic resonance spectra "NMRShiftDB". 43,581 NORMAN SLE NORMAN Suspect List Exchange environmental monitoring
Merck (NYSE: MRK) Q3 2024 Earnings Call Oct 31, 2024, 9:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants. Prepared Remarks: Operator. Thank you for standing by ...
In 1968, Aldrich Chemical Company published Volume 1, Number 1 edition of Aldrichimica Acta.The Acta both replaced Klarindex Sheets as a scientific journal meant specifically to keep chemists informed, as well as complemented the company's world-famous annual catalog, the Aldrich Handbook of Fine Chemicals.
Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.